Coeptis Therapeutics Holdings, Inc.
For the period ended Sep 30, 2025. Filed Nov 14, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 14, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
| Item 5. | Other Information |
|---|
Our directors and executive officers may from time to time enter into plans or other arrangements for the purchase or sale of our common stock that are intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act or may represent a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K).
On May 21, 2025, Daniel Yerace, our Vice President of Operations and a member of our Board of Directors, adopted a Rule 10b5-1 trading plan. Mr. Yerace’s Rule 10b5-1 trading plan provides for an active term commencing on August 31, 2025, and ending no later than February 11, 2027, for the sale of up to 20,000 shares of common stock of the Company.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.